-transparent.png){kind=logo}
The clinical and pathological features of metastatic prostate cancer with normal level of serum prostate-specific antigen (PSA) were investigated. Four patients with metastatic prostate cancer had serum PSA within the normal range at the diagnosis. All tumors were poorly-differentiated adenocarcinoma. Endocrine therapy was performed as the initial therapy in all patients. Despite subsequently treatment, all cases died of prostate cancer at 2, 8, 9 and 38 months. During disease progression, 3 of 4 patients had elevated serum markers such as carcinoembryonic antigen (CEA), CA19-9, CA15-3, CA125, neuron-specific enolase and pro-gastrin releasing peptide. Immunohistochemical examination of the initial biopsy specimens revealed that 4 and 3 cases were positive for CEA and chromogranin A, respectively. In advanced prostate cancer patients with low PSA level, those markers may aid in the follow up of disease.
R Nishio, and
Y Furuya, and
O Nagakawa, and
H Fuse
October 2005,
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
R Nishio, and
Y Furuya, and
O Nagakawa, and
H Fuse
February 2004,
Hospital medicine (London, England : 1998),
R Nishio, and
Y Furuya, and
O Nagakawa, and
H Fuse
November 1994,
Archives of pathology & laboratory medicine,
R Nishio, and
Y Furuya, and
O Nagakawa, and
H Fuse
May 1998,
Hinyokika kiyo. Acta urologica Japonica,
R Nishio, and
Y Furuya, and
O Nagakawa, and
H Fuse
May 2022,
Cureus,
R Nishio, and
Y Furuya, and
O Nagakawa, and
H Fuse
September 1998,
Urology,
R Nishio, and
Y Furuya, and
O Nagakawa, and
H Fuse
June 2024,
European urology oncology,
R Nishio, and
Y Furuya, and
O Nagakawa, and
H Fuse
January 1997,
European urology,
R Nishio, and
Y Furuya, and
O Nagakawa, and
H Fuse
October 2013,
Cancer epidemiology,
R Nishio, and
Y Furuya, and
O Nagakawa, and
H Fuse
September 2000,
The New England journal of medicine,
